QR Code

Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

Abstract Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic option in autoimmune disorders such as...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Julie Langlois, Simona Lange, Martin Ebeling, Will Macnair, Roland Schmucki, Cenxiao Li, Jonathan DeGeer, Tania J. J. Sudharshan, V. Wee Yong, Yun-An Shen, Christopher Harp, Ludovic Collin, James Keaney
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2024-10-01
Rangatū:Journal of Neuroinflammation
Ngā marau:
Multiple sclerosis
Fenebrutinib
BTK
Neuroinflammation
Microglia
Organoids
Urunga tuihono:https://doi.org/10.1186/s12974-024-03267-5
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite